A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m² and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma

References

• Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126:391.
   Web of Science ®Google Scholar
• Gay F, Magarotto V, Petrucci MT, et al. Autologous transplantation versus cyclophosphamide-lenalidomide-prednisone followed by lenalidomide-prednisone versus lenalidomide maintenance in multiple myeloma: long-term results of a phase III trial. Blood. 2015;126:392.
   Web of Science ®Google Scholar
• Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014;124:882–890.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Richardson PG, Laubach JP, et al. Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015;21:793–798.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–2955.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28:690–693.
   PubMed Web of Science ®Google Scholar
• Maybury B, Cook G, Pratt G, et al. Augmenting autologous stem cell transplantation to improve outcomes in myeloma. Biol Blood Marrow Transplant. 2016;22:1926–1937.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 2010;95:1913–1920.
   PubMed Web of Science ®Google Scholar
• Blanes M, Lahuerta JJ, Gonzalez JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19:69–74.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731–735.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol. 2000;109:138–147.
   PubMed Web of Science ®Google Scholar
• Salmon SE, Tesh D, Crowley J, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol. 1990;8:1575–1584.
   PubMed Web of Science ®Google Scholar
• Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park). 2000;14:101–108.
   PubMed Web of Science ®Google Scholar
• Wong JY, Liu A, Schultheiss T, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant. 2006;12:306–315.
   PubMed Web of Science ®Google Scholar
• Aydogan B, Mundt AJ, Roeske JC. Linac-based intensity modulated total marrow irradiation (IM-TMI). Technol Cancer Res Treat. 2006;5:513–519.
   PubMed Web of Science ®Google Scholar
• Wilkie JR, Tiryaki H, Smith BD, et al. Feasibility study for linac-based intensity modulated total marrow irradiation. Med Phys. 2008;35:5609–5618.
   PubMed Web of Science ®Google Scholar
• Aydogan B, Yeginer M, Kavak GO, et al. Total marrow irradiation with RapidArc volumetric arc therapy. Int J Radiat Oncol Biol Phys. 2011;81:592–599.
   PubMed Web of Science ®Google Scholar
• Yeginer M, Roeske JC, Radosevich JA, et al. Linear accelerator-based intensity-modulated total marrow irradiation technique for treatment of hematologic malignancies: a dosimetric feasibility study. Int J Radiat Oncol Biol Phys. 2011;79:1256–1265.
   PubMed Web of Science ®Google Scholar
• Wong JY, Forman S, Somlo G, et al. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2013;85:148–156.
   PubMed Web of Science ®Google Scholar
• Corvo R, Zeverino M, Vagge S, et al. Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiother Oncol. 2011;98:382–386.
   PubMed Web of Science ®Google Scholar
• Fogliata A, Cozzi L, Clivio A, et al. Preclinical assessment of volumetric modulated arc therapy for total marrow irradiation. Int J Radiat Oncol Biol Phys. 2011;80:628–636.
   PubMed Web of Science ®Google Scholar
• Rosenthal J, Wong J, Stein A, et al. Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood. 2011;117:309–315.
   PubMed Web of Science ®Google Scholar
• Somlo G, Spielberger R, Frankel P, et al. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res. 2011;17:174–182.
   PubMed Web of Science ®Google Scholar
• Wong JY, Rosenthal J, Liu A, et al. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009;73:273–279.
   PubMed Web of Science ®Google Scholar
• Hui SK, Kapatoes J, Fowler J, et al. Feasibility study of helical tomotherapy for total body or total marrow irradiation. Med Phys. 2005;32:3214–3224.
   PubMed Web of Science ®Google Scholar
• Patel P, Aydogan B, Koshy M, et al. Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014;20:2034–2041.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695.
   PubMed Web of Science ®Google Scholar
• Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radiosensitization with alkylating agents. Lancet. 1987;1:1149–1150.
   PubMed Web of Science ®Google Scholar
• Frassoni F, Scarpati D, Bacigalupo A, et al. The effect of total body irradiation dose and chronic graft-versus-host disease on leukaemic relapse after allogeneic bone marrow transplantation. Br J Haematol. 1989;73:211–216.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Vitale V, Corvo R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol. 2000;108:99–104.
   PubMed Web of Science ®Google Scholar
• Intensity Modulated Radiation Therapy Collaborative Working G. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914.
   PubMed Web of Science ®Google Scholar
• Lin SC, Hsieh PY, Shueng PW, et al. Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma. Biomed Res Int. 2013;2013:321762.
   PubMed Web of Science ®Google Scholar
• Shueng PW, Lin SC, Chong NS, et al. Total marrow irradiation with helical tomotherapy for bone marrow transplantation of multiple myeloma: first experience in Asia. Technol Cancer Res Treat. 2009;8:29–38.
   PubMed Web of Science ®Google Scholar
• Banfi A, Bianchi G, Galotto M, et al. Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment. Leuk Lymphoma. 2001;42:863–870.
   PubMed Web of Science ®Google Scholar